Preclinical candidates and targets for tuberculosis therapy

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a significant global health challenge, particularly in developing nations.
• The current drug discovery pipeline for new anti-TB compounds is notably limited.
• Existing strategies like broad-spectrum antibacterials show limited promise for advancing TB therapy.

Purpose of the Study:

• To review the current landscape of tuberculosis drug discovery.
• To identify promising avenues for developing novel anti-TB therapeutics.
• To highlight the potential of genomic information and new molecular targets.

Main Methods:

• Analysis of current drug discovery pipelines for tuberculosis.
• Review of the utility of genomic information in drug redesign.
• Exploration of new molecular targets and lead compounds.

Main Results:

• The portfolio of new TB compounds in development is insufficient for near-term clinical impact.
• Genomic information has aided in redesigning existing drugs like ethambutol.
• Current programs are investigating new targets such as the mycobacterial cell wall and non-replicating bacilli.

Conclusions:

• Developing new tuberculosis treatments requires innovative approaches beyond broad-spectrum agents.
• Leveraging genomic data and focusing on specific mycobacterial targets are crucial for future drug development.
• Further research into novel compounds targeting the cell wall and non-replicating forms of Mycobacterium tuberculosis is warranted.